Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 6Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Brain Neoplasms 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Solid Tumor, Adult 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Non-Small Cell Lung Cancer Metastatic 1Meningeal Neoplasms 1Melanoma 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1

Interventions

tislelizumab 1pembrolizumab 1patritumab deruxtecan 1leronlimab 1lenvatinib 1atezolizumab 1Tiragolumab 1Radiotherapy 1Cryosurgery 13-amino-1-methyl-3-(4-(3-phenyl-5H- imidazo(1,2-c)pyrido(3,4-e)(1,3)oxazin-2-yl)phenyl)cyclobutanol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Solid Tumor, Adult × patritumab deruxtecan × Clear all
NCT06383884 2025-12-15

Patritumab Deruxtecan in Patients With Solid Tumor Harboring an NRG1 Fusion

Samsung Medical Center

Phase 2 Recruiting
30 enrolled
Other solid neoplasm

Solid Tumor, Adult

Data powered by HemOnc (CC BY 4.0) Colophon âš¡